Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.43 |
| ▸ | FAAH | O00519 | 8/20 | 0.42 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.39 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287187 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL10614767 | 0.86 | — | — | |
| SCHEMBL27894388 | 0.86 | — | — | |
| SCHEMBL27894842 | 0.86 | — | — | |
| SCHEMBL23833732 | 0.86 | — | — | |
| Formaldehyde SCHEMBL27828588 | 0.84 | CES1 (0.44) | CES1FAAHNCEH1HDAC3HDAC4 | |
| Trifluoroacetic Acid SCHEMBL8358514 | 0.77 | CES1 (0.40) | CES1FAAHNCEH1HDAC3HDAC4 | |
| SCHEMBL28542223 | 0.77 | FAAH (0.50) | CES1FAAHNCEH1HDAC3HDAC4 | |
| Pyrimidine SCHEMBL29105565 | 0.77 | CES1 (0.43) | CES1FAAHNCEH1HDAC3HDAC4 | |
| Cysteine SCHEMBL360728 | 0.76 | PTGS1 (0.50) | CES1FAAHNCEH1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992518-B2 | Molecular vaccines for infectious disease | AGILENT TECHNOLOGIES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| EP-3334498-B1 | METHODS OF TREATING VOLUME DEPLETION AND KIDNEY INJURY | UNIV COLUMBIA (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11119104-B2 | Methods of treating volume depletion and kidney injury | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-09-14 | — | — | US | disclosed |
| US-10968269-B1 | MHC multimers in borrelia diagnostics and disease | AGILENT TECHNOLOGIES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210047383-A1 | MHC Multimers in Borrelia Diagnostics and Disease | DAKO DENMARK APS (DK) | 2021-02-18 | — | — | US | disclosed |
| US-20200347103-A1 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | AGILENT TECHNOLOGIES INC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10611818-B2 | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics | AGILENT TECHNOLOGIES, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190314471-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | AGILENT TECHNOLOGIES, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10369204-B2 | Molecular vaccines for infectious disease | DAKO DENMARK A/S (DK) | 2019-08-06 | — | — | US | disclosed |
| EP-3334498-A1 | METHODS OF TREATING VOLUME DEPLETION AND KIDNEY INJURY | The Trustees of Columbia University in the City of New York (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2003020901-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020900-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020953-A2 | COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020897-A2 | COMPOSITIONS AND METHODS RELATING TO OVARY SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020934-A1 | COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020899-A2 | COMPOSITIONS AND METHODS RELATING TO LUNG SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020102610-A1 | Automated identification of peptides | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-08-01 | — | — | US | disclosed |
| US-20020055186-A1 | Detection of peptides | OXFORD GLYCOSCIENCES (UK) LTD. | 2002-05-09 | — | — | US | disclosed |
| WO-2002025287-A2 | DETECTION OF PEPTIDES | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002021139-A2 | AUTOMATED IDENTIFICATION OF PEPTIDES | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-03-14 | — | — | WO | disclosed |